Cavendish has reiterated its positive stance on ANPCF, reaffirming forecasts for 2026 through 2028 and highlighting the potential for more than 300% upside from current levels. In a research note published last Friday, the broker emphasized ANPCF’s recovery trajectory, pointing to operational milestones in its cancer diagnostics programmes as key catalysts. The analysis notes that recent data-readiness events and regulatory submissions are on track, reinforcing confidence in the company’s medium-term revenue projections and underpinning investor sentiment.

ANPCF has reported a qualified sales pipeline valued at £12.6 million for fiscal years 2026/27, with a risk-weighted valuation of £4.5 million, as part of its preliminary results and outlook statement. The Guildford-based group underscored a sharpened commercial strategy focused on converting this pipeline into contracted revenue. Management also highlighted a strengthened balance sheet, citing sufficient cash reserves to fund both ongoing clinical studies and planned market expansion efforts throughout the next two years.